- Vouliez-vous dire
- level vaccines candidate
Résultats de la recherche - 6 results
Pre-registration efficacy study of a novel marker vaccine against classical swine fever on maternally derived antibody positive (MDA+) target animals.
efficacy of live attenuated vaccines against classical swine fever (CSF). For this reason, a marker vaccine candidate CP7_E2alf was tested for its efficacy in the presence of MDA. Pregnant sows were ...
Scalable chromatography-based purification of virus-like particle carrier for epitope based influenza A vaccine produced in Escherichia coli.
, Synthetic Vaccines, Virus-Like Particle Veterinary Medicine Viral Matrix Proteins Abstract: Virus-like particles (VLP s) are promising molecular structures for the design and construction of novel vaccines ...
The Genome of a Tortoise Herpesvirus (Testudinid Herpesvirus 3) Has a Novel Structure and Contains a Large Region That Is Not Required for Replication In Vitro or Virulence In Vivo.
each replicated in cell culture comparably to strain 1976. With the goal of testing the potential of the three forms as attenuated vaccine candidates, strain 4295 was inoculated intranasally into ...
Pre-registration efficacy study of a novel marker vaccine against classical swine fever on Maternally Derived Antibody negative (MDA-) target animals.
The level of protection was determined by the development of clinical signs, viraemia and rate of mortality. The vaccine candidate met the criteria of Ph. Eur Monograph 0065, “Swine-fever vaccine (live, ...
DNA vaccines against tuberculosis.
remains a major health problem and novel vaccination regimens are urgently needed. AREAS COVERED: DNA vaccines against TB have been tested in various preclinical models and strategies have been developed to ...
Novel GMO-Based Vaccines against Tuberculosis: State of the Art and Biosafety Considerations.
p.463-99 (2014) Abstract: Novel efficient vaccines are needed to control tuberculosis (TB), a major cause of morbidity and mortality worldwide. Several TB vaccine candidates are currently in clinical and ...